ArticleAbdominal radiology (New York)2026
Hepatobiliary phase radiomics for identifying subclinical liver dysfunction in compensated chronic liver disease: development and external validation.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo develop and externally validate a radiomics model derived from gadoxetic acid-enhanced hepatobiliary phase (HBP) MRI for detecting subclinical liver dysfunction in patients with compensated chronic liver disease (CLD).
methodsIn this retrospective study, patients were included based on Child-Pugh Class A status and absence of clinical decompensation. Subclinical liver dysfunction was defined using a composite reference standard integrating ALBI score ( > - 2.60), MELD-Na ≥ 10, and FIB-4 ≥ 2.67. Whole-liver radiomic features were extracted from HBP images. Feature selection and model development were performed using Boruta and class-weighted logistic regression within a nested cross-validation framework.
resultsA total of 138 individuals (90 patients with subclinical liver dysfunction and 48 controls) were analyzed. Six radiomic features were selected for model development. In the internal test cohort (n = 21), the model achieved a ROC-AUC of 0.86 [95% CI: 0.66-1.00] with an accuracy of 0.81 [95% CI: 0.62-0.95]. In the external validation cohort (n = 26), the model achieved a ROC-AUC of 0.89 [95% CI: 0.73-0.99] and an accuracy of 0.77 [95% CI: 0.58-0.92] using a fixed decision threshold. Both first-order and texture-based features were represented among the selected predictors.
conclusionHBP-derived radiomics demonstrates potential as a noninvasive biomarker for identifying subclinical liver dysfunction in compensated CLD patients. While the results are promising, the relatively small validation cohorts warrant cautious interpretation, and further validation in larger multicenter populations is required to confirm robustness and generalizability.
Indexed as
Identifiers
42081100What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.